GURU.Markets stock price, segment price, and overall market index valuation
The company's share price NeuroBo Pharmaceuticals
Notable Labs is a biotech company using a platform to tailor optimal cancer treatments. Its stock price is a bet on the success of its personalized medicine technology.
Share prices of companies in the market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. We've categorized it under "Neurology." The chart below shows how investors value companies in this complex field of medicine.
Broad Market Index - GURU.Markets
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. We've categorized it under "Neurology." The chart below shows how investors value companies in this complex field of medicine.
Change in the price of a company, segment, and market as a whole per day
NRBO - Daily change in the company's share price NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about its drug clinical trials.
Daily change in the price of a set of shares in a market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurological and cardiometabolic diseases. Neurology is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector.
Daily change in the price of a broad market stock, index - GURU.Markets
NeuroBo Pharmaceuticals is a biotech company working on treating neurological diseases. Its shares represent a venture bet on scientific success. Their high volatility, driven by expectations, contributes to the overall stock market's performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals' year-to-date performance tells the story of its diversified development portfolio. Its market cap change over the past 12 months reflects progress across its programs, from obesity treatments to cardiac treatments. Its valuation is a bet that at least one of its risky projects will reach the finish line.
Annual dynamics of market capitalization of the market segment - Neuro
As an early-stage biotech company, NeuroBo is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its drugs for neurological diseases. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
NeuroBo Pharmaceuticals, a biopharmaceutical company focused on drugs for neurological diseases, has a portfolio of several candidates. Its year-over-year market capitalization reflects progress across all of its programs and is less dependent on a single outcome.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization NeuroBo Pharmaceuticals
NeuroBo is a biopharmaceutical company focused on cardiometabolic diseases. Its monthly performance is entirely dependent on progress in its clinical programs. News of its drug trial results is the main driver.
Monthly dynamics of market capitalization of the market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of cardiometabolic and neurological diseases. The chart below shows the overall dynamics in the neuroscience sector, which is one of the most complex for drug development but has significant unmet needs.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Early-stage biotech stocks are a venture bet on science. The chart below shows investors' overall risk appetite. Is NeuroBo Pharmaceuticals moving at an extreme amplitude, amplifying market movements, as is typical for such stories?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization NeuroBo Pharmaceuticals
Shares of NeuroBo, a biotech company focused on treating neurological diseases, reflect the risks and opportunities in the field on a weekly basis. The stock is volatile and responds to clinical trial data and the company's ability to advance its candidates toward approval.
Weekly dynamics of market capitalization of the market segment - Neuro
NeuroBo Pharmaceuticals is a biotech company focused on treating neurodegenerative diseases. The chart will help isolate its own news-driven dynamics from the broader sector, showing how the market views its pipeline and its chances of success.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
NeuroBo Pharmaceuticals is a biopharmaceutical company. Its success depends on the results of clinical trials. This chart will help you understand: does NeuroBo live in its own world of scientific news, or are the overall market conditions and risk appetite in the biotech sector actually influencing its stock price?
Market capitalization of the company, segment and market as a whole
NRBO - Market capitalization of the company NeuroBo Pharmaceuticals
NeuroBo's market capitalization chart tells the story of a biotech company trying to find a new lease on life through acquisition after a series of setbacks. Its volatile dynamics reflect its ongoing search for a promising drug. Its trajectory reflects the market's assessment of the success rate of its latest bet in obesity treatment.
NRBO - Share of the company's market capitalization NeuroBo Pharmaceuticals within the market segment - Neuro
NeuroBo Pharmaceuticals is a biotech company focused on drugs for the treatment of neurological diseases. Its small share of the sector's market capitalization reflects its high risk and early stage development. The chart shows how its weighting changes based on drug news.
Market capitalization of the market segment - Neuro
NeuroBo Pharmaceuticals is a biotech company focused on treating neurological and cardiometabolic diseases. The chart below shows the overall market capitalization of this sector. Its dynamics serve as a backdrop against which NeuroBo is attempting to advance its drugs through complex and expensive clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
NeuroBo is a biotech company developing drugs for the treatment of neurological diseases. The market capitalization of such companies reflects investors' faith in the scientific hypothesis and the team. Their volatility on the overall chart reflects the long and risky path from idea to potential cure.
Book value capitalization of the company, segment and market as a whole
NRBO - Book value capitalization of the company NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals' foundation is its capital, which is dedicated to developing drugs for the treatment of cardiometabolic diseases such as obesity. This is a real, scientific foundation focused on one of the most pressing healthcare issues. How has this biotech asset changed since its shift in strategy? The chart below shows its dynamics.
NRBO - Share of the company's book capitalization NeuroBo Pharmaceuticals within the market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of neurological and cardiometabolic diseases. The chart shows the share of its R&D assets, reflecting the physical foundation of its scientific activity.
Market segment balance sheet capitalization - Neuro
NeuroBo, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual capital.
Book value of all companies included in the broad market index - GURU.Markets
NeuroBo's book value is derived from its patent portfolio and clinical trial data for drugs for the treatment of neurodegenerative diseases and cardiometabolic disorders. The company's assets represent capitalized science. The chart below shows how this biotech stacks up in terms of asset size.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a biotech company in clinical development. Its book value is the accumulated development costs. Its market capitalization is solely based on the hope for the success of its drugs. The chart shows how this speculative investor confidence changes with each news update on the trial's progress.
Market to book capitalization ratio in a market segment - Neuro
NeuroBo Pharmaceuticals is a biotech company with a portfolio of drugs for the treatment of neurodegenerative and cardiometabolic diseases. Its volatile price chart reflects speculative investor interest driven by news of clinical trials.
Market to book capitalization ratio for the market as a whole
NeuroBo Pharmaceuticals is a biotech company whose value depends almost entirely on the success of clinical trials. Its physical assets are minimal, and its market capitalization reflects its hopes for future drugs. This chart helps assess how high the risk and potential premium is in biotech compared to the broader market.
Debts of the company, segment and market as a whole
NRBO - Company debts NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, a clinical-stage biotech company, uses capital to develop its drugs for neurological and other diseases. This chart shows how the company, often after restructuring or changing focus, manages its limited resources to advance its most promising programs.
Market segment debts - Neuro
NeuroBo Pharmaceuticals is a biotech company focused on drugs for the treatment of neurodegenerative and cardiometabolic diseases. Being in the clinical stage, it, like its peers, relies on equity capital. This chart demonstrates that the company avoids debt to fund its risky but potentially breakthrough research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a biotech company focused on drugs for the treatment of neurodegenerative diseases. Its success depends entirely on the results of clinical trials. This chart shows the extent to which the company finances its expensive R&D with debt, which is a direct measure of its financial risk.
Market segment debt to market segment book capitalization - Neuro
NeuroBo Pharmaceuticals is a small biotech company developing drugs to treat neurodegenerative and cardiometabolic diseases. The chart illustrates how aggressively the sector uses debt to fund long-term, risky clinical trials, providing context for evaluating NeuroBo's strategy.
Debt to book value of all companies in the market
NeuroBo Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on neurological diseases, which require lengthy and expensive research. This chart, reflecting the overall market debt burden, allows one to assess how the company's financial strategy is typical for biotech, where revenue is deferred for years and R&D costs are high.
P/E of the company, segment and market as a whole
P/E - NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This chart shows how investors value its pipeline. This valuation is based on clinical trial results and the potential of its drug candidates.
P/E of the market segment - Neuro
This industry chart for biotech companies serves as a benchmark for NeuroBo. It reflects overall speculative valuations in the sector. Comparisons with it help understand how the market views NeuroBo's development pipeline, which is focused on treating metabolic and neurodegenerative diseases, and whether it believes in its commercial potential.
P/E of the market as a whole
NeuroBo Pharmaceuticals is a biopharmaceutical company developing drugs for the treatment of neurological and other diseases. Its valuation depends entirely on the success of its drugs in clinical trials. Overall market sentiment, reflected in this chart, is completely irrelevant. NeuroBo's fate is decided in the lab.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company NeuroBo Pharmaceuticals
The chart for NeuroBo Pharmaceuticals, a company developing drugs for neurodegenerative and cardiometabolic diseases, shows market expectations for its clinical programs. It reflects investor confidence in the potential of its candidates and their future commercial value.
%20P%2FE%20NeuroBo%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-NeuroBo-Pharmaceuticals&v=1772648023079 "Chart of the company's future (projected) P/E NeuroBo Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. The company's pipeline consists of several early-stage candidates. The chart shows industry forecasts. This helps assess how the market views NeuroBo's risky pipeline, where each development has the potential to succeed or fail.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772648023079 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on treating neurodegenerative diseases. Its valuation, like many companies in this field, depends on the success of clinical trials. This chart of overall risk appetite shows how willing investors are to fund capital-intensive research in this complex area.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772648023084 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on drugs for the treatment of neurodegenerative and cardiometabolic diseases. Being in the clinical stage, its financial results reflect research and development expenses. This chart shows the company's financial progress in the search for new treatments.
Profit of companies in the market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This graph, reflecting profitability in the neuroscience sector, demonstrates the complexity and risk involved in developing this field. Their success depends entirely on the clinical trial results of their promising candidates.
Overall market profit
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on drugs for the treatment of neurodegenerative diseases. Its portfolio includes candidates for various indications. The company's success depends on the results of clinical trials. This graph of overall market returns demonstrates how favorable the investment climate is for funding such risky projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a biotech company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. Its future depends on the results of clinical trials. This chart aggregates analyst opinions on the likelihood of success of its candidates, which is key to assessing the company's valuation.
%20profit%20of%20the%20company%20NeuroBo%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-NeuroBo-Pharmaceuticals&v=1772648023120 "Graph of future (projected) profit of the company NeuroBo Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
NeuroBo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative diseases and cardiometabolic disorders. Its future depends on the success of clinical trials. This biotech chart reflects overall investor sentiment and their willingness to fund risky developments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772648023132 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
NeuroBo Pharmaceuticals is a biotech company focused on neurodegenerative diseases. Its value is determined by the potential of its scientific developments. The overall economic climate, illustrated by this chart, influences the availability of capital to finance lengthy and risky clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772648023133 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. For a clinical-stage company, this chart is key. It shows how investors evaluate the potential of its developments, betting on future sales if successful.
P/S market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. The company's valuation is based on the future potential of its clinical candidates. This chart, which reflects the average valuation in the biotech industry, helps understand how investor expectations for NeuroBo's portfolio align with trends.
P/S of the market as a whole
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This chart, which reflects market revenue estimates, serves as a proxy for NeuroBo's expectations. It demonstrates the value investors place on the company's pipeline in anticipation of future clinical success.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This chart reflects investor expectations regarding the future success of its clinical programs, which are high-risk but also high-potential.
%20P%2FS%20NeuroBo%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-NeuroBo-Pharmaceuticals&v=1772648023157 "The graph of the company's future (projected) P/S NeuroBo Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
NeuroBo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This chart reflects average revenue expectations in the biotech sector. It allows investors to assess the market's perception of the potential of NeuroBo's pipeline.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772648023166 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This chart illustrates general market expectations. NeuroBo's success in clinical trials could lead to new treatments for millions of patients suffering from diabetic neuropathy and other conditions.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772648023167 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales NeuroBo Pharmaceuticals
This chart illustrates the revenue of NeuroBo Pharmaceuticals, a clinical-stage biotech focused on drugs for neurological and cardiometabolic diseases. At this stage, its revenue, if any, is generated from partnerships rather than commercial sales, reflecting development progress.
Sales of companies in the market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This chart shows revenue in the pharmaceutical sector. The company's developments target areas such as diabetic neuropathy, where there are significant unmet patient needs.
Overall market sales
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on treating neurodegenerative diseases. Its prospects depend on the success of clinical trials. The overall economic climate, reflected in this chart, influences the investment climate in the biotech sector, which influences the company's funding.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a biotechnology company focused on developing drugs for the treatment of neurodegenerative and metabolic diseases. Future revenue is dependent on the success of clinical trials. The chart reflects analyst expectations for the commercial potential of its developments.
%20sales%20of%20the%20company%20NeuroBo%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-NeuroBo-Pharmaceuticals&v=1772648023183 "Schedule of future (projected) sales of the company NeuroBo Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This chart shows the forecast for the entire neurological drug market, where there is a huge need for new therapies for conditions such as diabetic neuropathy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772648023206 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
NeuroBo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and cardiometabolic diseases. Its valuation depends on the success of clinical trials. This price chart, reflecting market sentiment, influences the availability of capital and investor willingness to fund risky biotech projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772648023207 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a biotech company developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. Being in clinical trials, it incurs significant R&D expenses. This chart shows its net losses—the price the company pays for the long and risky path to developing new drugs.
Market segment marginality - Neuro
NeuroBo Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. Profitability is a long-term goal. This chart reflects clinical trial costs. Investors analyze it to assess the scientific potential of their pipeline.
Market marginality as a whole
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. Their portfolio includes molecules for various indications. This overall profitability chart is irrelevant for them. Their value and prospects are determined solely by clinical trial results.
Employees in the company, segment and market as a whole
Number of employees in the company NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals is a clinical-stage biotech company. It operates with a very compact team, which allows it to minimize R&D costs. This chart illustrates a typical model for a small biotech, focused on advancing a few key assets.
Share of the company's employees NeuroBo Pharmaceuticals within the market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This chart reflects its share of the total number of researchers in these areas. It is an indicator of the scale of its current clinical programs and the size of the scientific team working on new drugs.
Number of employees in the market segment - Neuro
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative and cardiometabolic diseases. This chart shows employment trends in the pharmaceutical sector. Fluctuations in the hiring of scientists and clinicians reflect progress (or lack thereof) in clinical trials, which are a key driver for such companies.
Number of employees in the market as a whole
NeuroBo Pharmaceuticals is a biotech company specializing in drugs for the treatment of neurological diseases. Its future depends on the success of clinical trials. The overall economic environment, reflected in this chart, influences investor sentiment and their willingness to fund long-term, risky research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company NeuroBo Pharmaceuticals (NRBO)
NeuroBo Pharmaceuticals is a biotech company whose portfolio focuses on drugs for the treatment of neurological and metabolic disorders. Like other R&D companies, its staff is small, and its value is determined not by revenue but by the potential of its developments. This chart shows the high value the market places on intellectual property (patents) per scientist working on future drugs.
%20of%20the%20company%20NeuroBo%20Pharmaceuticals%20(NRBO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-NeuroBo-Pharmaceuticals-NRBO&v=1772648023240 "Chart of market capitalization per employee (in thousands of dollars) of the company NeuroBo Pharmaceuticals (NRBO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative diseases. Like many companies in this sector, its value is determined by the potential of its clinical programs. This chart shows the market valuation of its research assets and prospects based on its small team of scientists.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772648023249 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on drugs for the treatment of neurological and viral diseases. The chart shows the company's valuation at the clinical stage. It reflects how the market perceives the potential success of their development pipeline, where the contribution of a small scientific team can create significant value.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772648023250 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company NeuroBo Pharmaceuticals (NRBO)
NeuroBo Pharmaceuticals is a clinical-stage biotech company developing drugs for the treatment of metabolic (MASH) and neurodegenerative diseases. This is R&D. This chart shows the company's capital burn rate: the amount of capital the company spends on each scientist during expensive clinical trials.
%20Chart%20NeuroBo%20Pharmaceuticals%20(NRBO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-NeuroBo-Pharmaceuticals-NRBO&v=1772648023253 "Company Profit Per Employee (in thousands of dollars) Chart NeuroBo Pharmaceuticals (NRBO)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
NeuroBo Pharmaceuticals is a biotech company focused on drugs for the treatment of neurodegenerative and cardiometabolic diseases. Being in clinical development, the company is not profitable. This metric (loss per employee) reflects the cost of conducting scientific research.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772648023263 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
NeuroBo Pharmaceuticals is a clinical-stage biotech company specializing in neuroscience and, more recently, weight loss drugs. It's an R&D company. The company is not profitable. This chart shows the company's capital burn rate: the operating loss per research team developing the new drug.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772648023272 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee NeuroBo Pharmaceuticals (NRBO)
NeuroBo Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of neurodegenerative and cardiometabolic diseases. This chart reflects the progress of monetizing its research. Revenue per employee dynamics will depend on the success of clinical trials and potential partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-NeuroBo-Pharmaceuticals-NRBO&v=1772648023279 "Sales chart per company employee NeuroBo Pharmaceuticals (NRBO)")
Sales per employee in the market segment - Neuro
NeuroBo Pharmaceuticals is a biotech company developing treatments for neurodegenerative and cardiometabolic diseases. While in the clinical stage, their revenue (if any) comes from partnerships. This chart shows how productive their R&D team is in monetizing their developments per scientist.
Sales per employee for the market as a whole
NeuroBo Pharmaceuticals (NRBO) is a biotech company with a diversified portfolio, including candidates for the treatment of diabetes and neurodegenerative diseases. The company is in the clinical stage. This chart illustrates a typical R&D situation: the company has no commercial revenue, and its entire research staff is focused on development and testing.
Short shares by company, segment and market as a whole
Shares shorted by company NeuroBo Pharmaceuticals (NRBO)
NeuroBo Pharmaceuticals is a biotech company developing drugs to treat neurodegenerative diseases. The bearish sentiment shown in this chart reflects investors' bets that its early-stage drug candidates will fail in clinical trials and ultimately fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-NeuroBo-Pharmaceuticals-NRBO&v=1772648023290 "Short Shares Chart for the Company NeuroBo Pharmaceuticals (NRBO)")
Shares shorted by market segment - Neuro
NeuroBo Pharmaceuticals is a biotech company focused on developing treatments for neurodegenerative diseases and cardiometabolic disorders. This chart measures the overall bearish sentiment in the biotech sector focused on metabolic and neurological disorders. It shows the level of market skepticism regarding the likelihood of clinical trial success in these challenging drug development areas.
Shares shorted by the overall market
NeuroBo (NRBO) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing NRBO will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator NeuroBo Pharmaceuticals (NRBO)
This oscillator for NeuroBo is a barometer of the hype surrounding Ozempic. The company failed in neuroscience and "bought" a weight loss drug (GLP-1) in an attempt to catch up with Novo Nordisk. "Overheating" (above 70) occurs with any announcement related to this program. Extreme competition and the early stage lead to "overselling."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-NeuroBo-Pharmaceuticals-NRBO&v=1772648023292 "RSI 14 indicator chart for the company's stock NeuroBo Pharmaceuticals (NRBO)")
RSI 14 Market Segment - Neuro
NeuroBo (NRBO) is a biotech company that has dramatically changed course. Starting in neuroscience, they entered the hot weight-loss market (GLP-1). This chart measures the pulse of the Neuroscience/Metabolism sector. It helps distinguish the dynamics of NRBO (which thrives on the "weight-loss" hype) from general "overheating" or "overselling" in biotech.
RSI 14 for the overall market
For NeuroBo, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NRBO (NeuroBo Pharmaceuticals)
NeuroBo (NRBO) is a biotech developing a pipeline of drugs, including candidates for the treatment of neurodegenerative diseases and (most notably) obesity (a GLP-1 analog). This chart shows the average target price. It reflects analysts' speculative assessments of the chances of success in clinical trials for its drugs in these competitive areas.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NRBO-NeuroBo-Pharmaceuticals&v=1772648023308 "A chart showing analyst consensus forecasts for the expected stock price. NRBO (NeuroBo Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price NRBO (NeuroBo Pharmaceuticals)
NeuroBo (NRBO) is a biotech company developing drugs for the treatment of neurodegenerative and cardiometabolic diseases (MASH, diabetes). This chart shows how the current share price differs from its "fair" value. It reflects analysts' "venture capital" assessment of their R&D portfolio and the chances of clinical success.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NRBO-NeuroBo-Pharmaceuticals&v=1772648023309 "A chart showing the difference between the consensus forecast and the actual stock price. NRBO (NeuroBo Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
NeuroBo is a biotech company that, after its pivot, focused on R&D for obesity (GLP-1) and cardiology treatments. This is a highly competitive R&D company. This chart shows analysts' overall expectations for the *entire* neuroscience (and metabolism) sector. It reflects whether experts believe junior companies will succeed in the weight loss market.
Analysts' consensus forecast for the overall market share price
NeuroBo (NRBO) is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases and metabolic disorders. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market and serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index NeuroBo Pharmaceuticals
NeuroBo is a biotech incubator. They don't have a single selling point; their business is discovering, acquiring (M&A), and developing (R&D) drug candidates in hot niches (neurology, cardiometabolic). This chart is a summary indicator of their R&D arbitrage. It reflects their ability to pick winners and their (very risky) progress in clinical trials.
AKIMA Market Segment Index - Neuro
NeuroBo Pharmaceuticals is a neurobiotech focused on treating diabetic neuropathy and other neurological disorders. In this complex R&D field, risks are high. This chart compares their composite index to the sector average, allowing you to assess how their drug pipeline compares to the competition.
The AKIM Index for the overall market
NeuroBo Pharmaceuticals is a biotech company developing treatments for cardiometabolic diseases (MASH, obesity) and neuropathic pain. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this speculative story, which has entered the obesity treatment race, fits in with overall economic trends.
